Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics

References

• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry20097099099619497244
   PubMed Web of Science ®Google Scholar
• NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand200711526026717355516
   PubMed Web of Science ®Google Scholar
• NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaPsychiatry Res201017610911320185182
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv20045588689115292538
   PubMed Web of Science ®Google Scholar
• BuchananRWKreyenbuhlJKellyDLThe 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull201036719319955390
   PubMed Web of Science ®Google Scholar
• VelliganDIWeidenPJSajatovicMThe expert consensus guideline series: adherence problems in patients with serious and persistent mental illnessJ Clin Psychiatry20097014619686636
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trialsSchizophr Res2011127839221257294
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry201116860360921362741
   PubMed Web of Science ®Google Scholar
• KaneJMEerdekensMLindenmayerJPKeithSJLesemMKarcherKLong-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychoticAm J Psychiatry20031601125113212777271
   PubMed Web of Science ®Google Scholar
• SimpsonGMMahmoudRALasserRAA 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorderJ Clin Psychiatry2006671194120316965196
   PubMed Web of Science ®Google Scholar
• FleischhackerWWEerdekensMKarcherKTreatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychoticJ Clin Psychiatry2003641250125714658976
   PubMed Web of Science ®Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol20101363564719941696
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol20102524725620389255
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol20103023524420473057
   PubMed Web of Science ®Google Scholar
• CitromeLPaliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medicationInt J Clin Pract20106421623919886879
   PubMed Web of Science ®Google Scholar
• GopalSGassmann-MayerCPalumboJSamtaniMNShiwachRAlphsLPractical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophreniaCurr Med Res Opin20102637738720001492
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res201011610711719959339
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals IncInvega^® Sustenna^® (paliperidone palmitate) extended-release injectable suspensionTitusville, NJJanssen Pharmaceuticals Inc82012
   Google Scholar
• Janssen Pharmaceuticals IncRisperdal^® Consta^® (risperidone) long-acting injectionTitusville, NJJanssen Pharmaceuticals Inc62012
   Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113521822621092748
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text RevisionWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull1987132612763616518
   PubMed Web of Science ®Google Scholar
• MarderSRDavisJMChouinardGThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trialsJ Clin Psychiatry1997585385469448657
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology (028 Clinical Global Impressions [CGI])1976218222
   Google Scholar
• MorosiniPLMaglianoLBrambillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioningActa Psychiatr Scand200010132332910782554
   PubMed Web of Science ®Google Scholar
• SliwaJKBossieCAMaYWAlphsLEffects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidoneSchizophr Res2011132283421775106
   PubMed Web of Science ®Google Scholar
• MollerHJLlorcaPMSacchettiEMartinSDMedoriRParelladaEEfficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapiesInt Clin Psychopharmacol20052012113015812261
   PubMed Web of Science ®Google Scholar
• van OsJBossieCALasserRAImprovements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidoneInt Clin Psychopharmacol20041922923215201570
   PubMed Web of Science ®Google Scholar
• De MarinisTSaleemPTGluePSwitching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophreniaPharmacopsychiatry20074025726318030649
   PubMed Web of Science ®Google Scholar
• SchmaussMSacchettiEKahnJPMedoriREfficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidoneInt Clin Psychopharmacol200722859217293708
   PubMed Web of Science ®Google Scholar
• Grimaldi-BensoudaLRouillonFAstrucBDoes long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)Schizophr Res201213418719422130111
   PubMed Web of Science ®Google Scholar
• RosenheckRAKrystalJHLewRLong-acting risperidone and oral antipsychotics in unstable schizophreniaN Engl J Med201136484285121366475
   PubMed Web of Science ®Google Scholar
• CanusoCMGrinspanAKalaliAMedication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidoneInt Clin Psychopharmacol20102515516420216424
   PubMed Web of Science ®Google Scholar
• CanusoCMYoussefEABossieCATurkozISchreinerASimpsonGMPaliperidone extended-release tablets in schizophrenia patients previously treated with risperidoneInt Clin Psychopharmacol20082320921518545059
   PubMed Web of Science ®Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry Suppl200952S63S6719880920
   PubMedGoogle Scholar
• EreshefskyLMascarenasCAComparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamicsJ Clin Psychiatry200364182314680415
   PubMed Web of Science ®Google Scholar
• SamtaniMNVermeulenAStuyckensKPopulation pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychoticClin Pharmacokinet20094858560019725593
   PubMed Web of Science ®Google Scholar
• McEvoyJPRisks versus benefits of different types of long-acting injectable antipsychoticsJ Clin Psychiatry200667 Suppl 5151816822092
   PubMed Web of Science ®Google Scholar
• HoughDLindenmayerJPGopalSSafety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaProg Neuropsychopharmacol Biol Psychiatry2009331022103119481579
   PubMed Web of Science ®Google Scholar